Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy
OBJECTIVE: To analyse the survival outcomes of women with ovarian carcinosarcoma according to platinum or doxorubicin based adjuvant chemotherapy protocols. STUDY DESIGN: This retrospective study was performed at Etlik Zübeyde Hanım and Zekai Tahir Burak Women’s Health Education and Research Hospi...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical Network
2015-04-01
|
| Series: | Gynecology Obstetrics & Reproductive Medicine |
| Subjects: | |
| Online Access: | https://gorm.com.tr/index.php/GORM/article/view/43 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | OBJECTIVE: To analyse the survival outcomes of women with ovarian carcinosarcoma according to platinum or doxorubicin based adjuvant chemotherapy protocols.
STUDY DESIGN: This retrospective study was performed at Etlik Zübeyde Hanım and Zekai Tahir Burak Women’s Health Education and Research Hospitals, which are tertiary centers in Turkey. A total of 31 women with ovarian carcinosarcoma between January 1999 and January 2013 were evaluated retrospectively.
RESULTS: The mean age of patients was 53.84±10.13. Most of the patients were diagnosed with stage IIIC ovarian carcinosarcoma (n=21, 67.7%). Maximal debulking and optimal debulking was performed to 23 (74.2%) and 8 (25.8%) patients, respectively. Disease free survival was significantly shorter in stage IIIC patients when compared to stage IIIB patients (p=0.048). Disease free survival for one and three years according to the treatment protocol (platinum or doxorubicin based) was not significantly different (p=0.574). Additionally, three and five years overall survival was not significantly different (p=0.891) between the platinum and doxorubicin based chemotherapy protocols.
DISCUSSION: We did not find a significant difference in terms of disease free survival and overall survival between platinum and doxorubicin based adjuvant chemotherapy protocols in women with ovarian carcinosarcoma.
|
|---|---|
| ISSN: | 1300-4751 2602-4918 |